Perrigo bought the rights to Entocort, a drug for mild to moderate Crohn’s disease, for $380 million. Additionally, Perrigo plans to acquire generic Entocort capsules marketed by Par Pharmaceuticals.
“Our agreement with Perrigo completes the global divestment of Entocort, emphasizing our strategic focus on three main therapy areas and providing further simplification of our supply chain,” Luke Miels, an AstraZeneca executive vice president.
More articles on gastroenterology:
7 ways 2016 CMS payment updates affect gastroenterology
Defining moments: The top 2015 highlights in GI
4 GI physicians in the news – Nov. 20, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.